Neutrophil-to-Lymphocyte Ratio and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant Chemotherapy

Michalis Liontos (mliontos@gmail.com)
National and Kapodistrian University of Athens: Ethniko kai Kapodistriako Panepistemio Athenon

Angeliki Andrikopoulou
National and Kapodistrian University of Athens: Ethniko kai Kapodistriako Panepistemio Athenon

Konstantinos Koutsoukos
National and Kapodistrian University of Athens: Ethniko kai Kapodistriako Panepistemio Athenon

Christos Markellos
National and Kapodistrian University of Athens: Ethniko kai Kapodistriako Panepistemio Athenon

Efthymia Skaﬁda
National and Kapodistrian University of Athens: Ethniko kai Kapodistriako Panepistemio Athenon

Oraianthi Fiste
National and Kapodistrian University of Athens: Ethniko kai Kapodistriako Panepistemio Athenon

Maria Kaparelou
National and Kapodistrian University of Athens: Ethniko kai Kapodistriako Panepistemio Athenon

Nikolaos Thomakos
National and Kapodistrian University of Athens: Ethniko kai Kapodistriako Panepistemio Athenon

Dimitrios Haidopoulos
National and Kapodistrian University of Athens: Ethniko kai Kapodistriako Panepistemio Athenon

Alexandros Rodolakis
National and Kapodistrian University of Athens: Ethniko kai Kapodistriako Panepistemio Athenon

Meletios-Athanasiou Dimopoulos
National and Kapodistrian University of Athens: Ethniko kai Kapodistriako Panepistemio Athenon

Flora Zagouri
National and Kapodistrian University of Athens: Ethniko kai Kapodistriako Panepistemio Athenon

Research

Keywords: Neutrophil-to-Lymphocyte, Neoadjuvant Chemotherapy, ovarian cancer, prognostic markers

DOI: https://doi.org/10.21203/rs.3.rs-667991/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is the recommended approach in patients with advanced epithelial ovarian cancer (EOC). However, most patients eventually relapse despite the initial high response rate to chemotherapy. Chemotherapy response score (CRS) and neutrophil-to-lymphocyte ratio (NLR) have been identified as potential biomarkers of platinum resistance and disease prognosis. We retrospectively evaluated 132 patients with stage IIIC or IV ovarian/fallopian tube/primary peritoneal cancer who had received NACT followed by IDS from 01/01/2003 to 31/12/2018. CRS was assessed on omental specimens collected from IDS according to ICCR guidelines.

Results

Median age was 64.57 years (SD: 9.72; range 39.2 - 87.1). Most ovarian tumors were serous epithelial (90.9%; 120/132). An elevated NLR (defined as > 3) was observed in 72% (95/132) of patients in contrast with 28% (37/132) of patients characterized by low NLR status. Median PFS (mPFS) and median overall survival (mOS) were 13.05 months (95% CI: 11.42-14.67)) and 34.69 months (95% CI: 23.26 - 46.12) respectively. In univariate analysis, CRS3 score was significantly associated with prolonged mPFS (CRS1/2: 12.79 months vs CRS3: 17.7 months; P= 0.008). CRS score was not associated with mOS (P=0.876). High NLR was not significantly associated with mPFS (P=0.128), however it was significantly associated with poor mOS (P=0.012). In multivariate analysis, only performance of surgery maintained its statistical significance with both PFS (P=0.001) and OS (P=0.008).

Conclusion

NLR could serve as a useful predictor of OS but not PFS in ovarian cancer patients receiving NACT. In accordance with our previous study, CRS score at omentum was found to be associated with PFS but not OS in ovarian cancer patients treated with NACT and IDS.

Highlights

Biomarkers that would predict response to neoadjuvant chemotherapy in advanced ovarian cancer patients are eagerly needed:

- Neutrophil to Lymphocyte Ratio (NLR) is an indicator of systemic inflammatory response to the malignancy
- NLR was evaluated in 132 patients undergoing Neoadjuvant Chemotherapy for advanced ovarian cancer
- Elevated NLR was associated with worse prognosis
- No association between NLR and response to chemotherapy was noted

Background

Ovarian cancer is the eighth most common cause of cancer-related mortality in women globally and the leading cause of gynecological cancer-associated mortality in developed countries [1]. It is estimated that in 2020, about 308,069 new cases of ovarian cancer will be diagnosed and approximately 193,811 deaths will be reported worldwide [2]. Epithelial ovarian cancer (EOC) accounts for the 90% of ovarian cancers with high-grade serous ovarian carcinoma consisting the main histological subtype [3]. Despite the progress of cancer treatment during the last decade, over than two thirds of EOC cases are diagnosed at an advanced stage resulting in a 5-year survival rate of only 25% in stage III and IV disease [4]. The recommended approach for advanced-stage EOC is primary debulking surgery (PDS) followed by platinum-based chemotherapy. However, neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) proved to be non-inferior to primary debulking surgery in stage III/IV patients unable to undergo optimal cytoreduction during PDS [5–9]. NACT approach consists of three or four cycles of upfront chemotherapy followed by IDS with the goal of complete resection. Despite the initial response to chemotherapy (~ 85%), most patients eventually relapse [10]. Therefore, there is an emerging need for markers and prognostic factors evaluating the response to treatment.

Chemotherapy response score (CRS) is a three-tier histopathological scoring system for validating response to NACT [11]. Patients that achieve CRS3 after NACT have improved progression free survival (PFS) and Overall Survival (OS) according to several retrospective studies and their metanalysis [12, 13, 22, 23, 14–21]. On that basis, the International Collaboration on Cancer Reporting (ICCR) incorporated the use of the CRS system in the current ovarian cancer histopathology reporting guide [13]. It would be of interest though to identify biomarkers that could predict which patients will or will not achieve CRS3 after NACT. That would allow patient selection through clinical trials for alternative therapeutic approaches aiming at improving dismal prognosis of these patients.

Recently, our group has shown that lymphocytic infiltration in pre-chemotherapy biopsies is associated with CRS3 after NACT. This indicates that response to chemotherapy could be associated with the immunological response and the inflammatory milieu of the tumor. Neutrophil-to-lymphocyte ratio (NLR) that serves as a measure of systemic inflammatory response is a prognostic biomarker that has been widely explored in oncology. NLR is easily measured through a complete blood count and could be determined under most circumstances. In ovarian cancer patients, there is evidence supporting preoperative NLR clinical utility not only in outcome prediction [24–32] but also in distinguishing benign from malignant ovarian tumors [33–35]. NLR has been associated with CD4 + helper T cells (Th17) count and IL-8 and IL-6 plasma concentration [36, 37], levels of stromal IL-2 [38] and serum fibrinogen [39]. Overall, higher NLR values positively correlated with platinum resistance and poor prognosis.
In this context, we evaluated the predictive and prognostic role of NLR in advanced ovarian cancer patients treated with NACT followed by IDS and examined its association with CRS.

**Methods**

We retrospectively identified patients with stage IIIC or IV ovarian/fallopian tube/primary peritoneal cancer who had received NACT followed by IDS during a 15-year period (January 2003-December 2018) in our institutional database. Patients with coexisting hematological malignancies, systemic administration of corticosteroids or any inflammatory conditions that could affect blood counts were excluded. Our institution has been certified by the European Society of Gynecologic Oncology (ESGO) as a center of excellence for the treatment of ovarian cancer. Patients were selected for NACT and IDS if it was judged by the experienced Gynecologic Oncologists that they could not be debulked upfront to no residual tumor. Assessment involved imaging studies and/or laparoscopic evaluation. At least 3 cycles of NACT and adequate pathology specimens were required for inclusion to the analysis. IDS was performed at 4–6 weeks from last dose of chemotherapy. Since 2013, that bevacizumab administration in the frontline setting became the standard of care in the country, all patients were planned to receive bevacizumab post IDS, unless contraindicated. All women had provided informed consent for their treatment as well as for their use of medical records for research purposes. Clinicopathological characteristics including age at diagnosis, stage and histology of the disease, CA125 at diagnosis, residual disease at IDS, BRCA mutation status, type of chemotherapy administered, neutrophil and lymphocyte count prior to neoadjuvant chemotherapy, progression of the disease and overall survival were collected from the medical records of the patients. Optimal debulking was defined as maximum residual tumor < 1cm in diameter after IDS.

**Pathology review**

Tissue slides collected from IDS were thoroughly reviewed by an experienced gynecologic pathologist trained in assessment of Bohm's score (MS). CRS was assessed on omental specimens according to ICCR guidelines [13].

**Neutrophil to Lymphocyte Ratio evaluation**

Complete blood cell counts (CBC) were collected from all patients prior to commencing chemotherapy. NLR was defined as the absolute neutrophil count divided by the absolute lymphocyte count. An elevated NLR was defined as an NLR >3 based on previous studies [40–44].

**Statistical Analysis**

Continuous variables were summarized with the use of descriptive statistical measures [median and percentiles (25th, 75th)] and categorical variables were displayed as frequency tables (N, %). The outcome of the debulking surgery was classified as complete (no residual disease) or optimal (residual disease below 1cm). Overall Survival (OS) was defined as the time between the start of chemotherapy and the date of death from any cause. Progression-free Survival (PFS) was defined as the time between the start of chemotherapy and the date of progression. Alive patients were censored at the date of last contact. Kaplan-Meier estimates were used to describe and visualize the effect of categorical variables on OS and PFS. Log-rank tests were used to explore the prognostic value of categorical variables on clinical outcomes. The association of these factors with OS was assessed through HRs and their 95% confidence intervals estimated from univariate Cox proportional hazards models. Interactions between covariates and time varying effects were studied. Multivariable Cox-regression model of CRS omentum adjusted for age, Stage, and Debulking surgery was presented. Proportional hazards (PH) assumption was graphically assessed using plots of -\ln{-\ln(survival)} curves for each category of the covariates versus ln (analysis time). All statistical analyses were performed using the STATA/SE 16.0 software (Copyright 1985–2019 StataCorp LP).

**Results**

**Patient Baseline Characteristics**

Overall, 132 ovarian cancer patients treated with NACT were identified. Demographic, clinical and pathologic characteristics are presented in Table 1. In brief, median age was 64.57 years (SD: 9.72; range 39.2–87.1). Most ovarian tumors were serous epithelial (90.9%; 120/132), while there were isolated cases of endometroid (0.8%; 1/132), poorly differentiated (1.5%; 2/132) tumors and nine cases (6.8%) where histological subtype was not specified. Ninety patients (68.2%) had stage IIIC disease and 41 patients (31.1%) had stage IV disease.

A significant percentage of patients had performance status (PS) ≤1 in our cohort (ECOG 0: 38.6%; 51/132 and ECOG 1: 31.8%; 42/132 respectively). Overall, 78% (103/132) of patients treated with three or four cycles of NACT eventually underwent IDS. The remaining 29 patients (22%) never received a debulking surgery either due to rapid clinical deterioration and death prior to surgery, failure to achieve a disease regression to a surgically resectable extent or due to patients' preference. Debulking was optimal in 58.2% (60/103) of the cases and suboptimal in 32% (33/103). Initial chemotherapy consisted of paclitaxel/carboplatin in the majority of cases (85.6%; 113/132) while the remaining received carboplatin monotherapy. Testing for BRCA1/2 mutations was conducted in 34.8% of cases (46/132). BRCA mutations were detected in 11 cases (8.3%). Bevacizumab was administered in 31.8% (42/132) of patients either as first line maintenance treatment or as a subsequent line.

CRS score was available in 73 cases. 19 (26%), 31(42.5%) and 23 (31.5%) patients had ovarian CRS of 1, 2 and 3 respectively. Patients were classified in two distinct groups: one group with CRS1/2 (68.5%; 50/73) versus those with CRS3 (31.5%; 23/73).

**NLR and its associations with clinical characteristics in ovarian cancer**
Median value of neutrophil-to-lymphocyte ratio (NLR) was 4.18 (SD: 3.38; range 1.1–23.8). An elevated NLR (defined as > 3) was observed in 72% (95/132) of patients in contrast with 28% (37/132) of patients characterized by low NLR status. Attempting to dissect the population of patients with high NLR, we evaluated the association of NLR with clinicopathological factors. High NLR was significantly associated with poor performance status (ECOG-PS≥2) (P = 0.001), but not stage (P = 1.000) or age (P = 0.441). In relation to the applied treatments, high NLR was not associated with monotherapy carboplatin as initial chemotherapy (P = 0.380) but was statistically significantly correlated with inability to perform debulking surgery (P = 0.019), and omission of bevacizumab as a maintenance treatment (P = 0.004). For the 73 cases that CRS data were available, no statistical significant association with NLR was shown (P = 0.321).

**Survival Analysis**

Overall, median PFS (mPFS) was 13.05 months (95% CI: 11.42–14.67). In univariate analysis, NLR was not significantly associated with mPFS (P = 0.128) (Fig. 1). mPFS was 14.56 months in patients with low NLR (NLR < 3) (95% CI: 11.44–17.67) in contrast to 12.39 months (95% CI: 10.64–14.13) in the high NLR population. In contrast, CRS3 score was significantly associated with prolonged mPFS (CRS1/2: 12.79 months vs CRS3: 17.7 months; P = 0.008), along with other clinical parameters and treatment characteristics such as performance of surgery (P < 0.001), bevacizumab administration (P = 0.02), ECOG performance status <2 (P = 0.061) and presence of BRCA1/2 mutations (P = 0.003) (Fig. 2).

In the total population, median overall survival (mOS) was 34.69 months (95% CI: 23.26–46.12). High NLR status was significantly associated with poor mOS (P = 0.012). Median OS was 47.18 months for patients with low NLR values before chemotherapy initiation (95% CI: 32.77–61.59; SD: 7.35) versus 30.59 months in patients with high NLR (95% CI: 23.36–37.82; SD: 3.68) (Fig. 3).

In univariate analysis, CRS score was not associated with mOS (P = 0.876) (Fig. 4). Performance status (ECOG ≤1) (P < 0.001), bevacizumab administration (P < 0.001) and surgery (P < 0.001) demonstrated a strong correlation with mOS. In contrast, age over 65 (P = 0.129) and quality of debulking (P = 0.568) was not significantly associated with mOS.

In multivariate analysis, performance of surgery was the single factor statistically significantly associated with both PFS (P = 0.001) (Table II) and OS (P = 0.008) (Table III). NLR failed to maintain its statistical significance on multivariate analysis.

**Table I. Baseline Characteristics**
| Characteristics          | No. of patients (%) |
|-------------------------|---------------------|
| **Age (yr)**            |                     |
| Median                  | 64.57               |
| Range                   | 39.2 - 87.1         |
| **Histological type**   |                     |
| HGSC                    | 120 (90.9%)         |
| Endometrioid            | 1 (0.8%)            |
| Undifferentiated        | 2 (1.5%)            |
| Not specified           | 9 (6.8%)            |
| **FIGO stage**          |                     |
| IIIC                    | 90 (68.2%)          |
| IV                      | 41 (31.1%)          |
| Not specified           | 1 (0.8%)            |
| **Regimen of NAC**      |                     |
| Taxane+carboplatin      | 113 (85.6%)         |
| Other                   | 16 (12.1%)          |
| Not specified           | 3 (2.3%)            |
| **Surgery**             |                     |
| Yes                     | 103 (78%)           |
| No                      | 29 (22%)            |
| **ECOG score**          |                     |
| 0-1                     | 93 (70.4%)          |
| 2-3                     | 25 (18.9%)          |
| 4                       | 2 (1.5%)            |
| Not specified           | 12 (9.1%)           |
| **NLR**                 |                     |
| £3                      | 37 (28%)            |
| >3                      | 95 (72%)            |
| **CRS**                 |                     |
| CRS1/2                  | 50 (68.5%)          |
| CRS3                    | 23 (31.5%)          |
| **Debulking**           |                     |
| Optimal                 | 60 (58.2%)          |
| Suboptimal              | 33 (32%)            |
| Not specified           | 10 (9.7%)           |
Table II. Multivariate analysis for PFS

|                        | 95% CI               |
|------------------------|----------------------|
|                        | p Value  | Lower | Upper |
| Bevacizumab administration | .275     | .466   | 1.243 |
| ECOG score             | .323     | .355   | 1.406 |
| Surgery                | .001     | 1.704  | 6.973 |
| Age > 65               | .413     | .769   | 1.893 |
| NLR                    | .903     | .618   | 1.724 |
| FIGO stage             | .229     | .836   | 1.044 |

Table III. Multivariate analysis for OS

|                        | 95% CI               |
|------------------------|----------------------|
|                        | p Value  | Lower | Upper |
| Bevacizumab administration | .134     | .309   | 1.169 |
| ECOG score             | .271     | 719    | 3.231 |
| Surgery                | .008     | 1.287  | 5.201 |
| Age > 65               | .732     | .632   | 1.921 |
| NLR                    | .569     | .632   | 2.302 |
| FIGO stage             | .784     | .859   | 1.122 |

Discussion

Systemic inflammation caused by malignancies is often expressed as neutrophilia, thrombocytosis and relative lymphocytopenia in the peripheral blood [45, 46]. Neutrophils contribute to the development of an inflammatory microenvironment, promoting tumor growth, vascularization and metastasis. In addition, neutrophils attenuate the immune system by suppressing CD8 + T lymphocyte antitumor response through the release of nitric oxide synthase (iNOS) or arginase 1 (ARG1) [47]. Neutrophils facilitate tumor initiation and proliferation by producing MMP9 and transferring neutrophil elastase to cancer cells. In ovarian cancer patients, neutrophils possess intensified functions such as increased reactive oxygen species (ROS) production and increased adhesive ability [48] and may be implicated in disease progression by spreading to the omentum as early as before metastasis becomes detectable [49]. Neutrophils become abundant in the omentum and facilitate ovarian cancer cell implantation. Simultaneously, lower counts of lymphocytes may be related to the existence of a primary immunodeficiency. Lymphocytopenia may imply a poor lymphocyte-mediated immune response to malignancy and therefore an increased possibility of tumor recurrence. In this context, NLR was used as a representative index of inflammation and was evaluated in ovarian cancer. Interestingly, NLR has been proposed as useful marker for the preoperative discrimination of ovarian masses [50–52]. High NLR ratio could serve as an accurate discriminator of malignant ovarian masses in the preoperative setting.

We conducted this retrospective study to evaluate the role of CRS and NLR as independent biomarkers in advanced ovarian cancer patients treated with NACT and IDS. On univariate analysis, NLR (high NLR > 3 vs low NLR ≤ 3) was significantly associated with OS (P = 0.012). In addition, NLR inversely
correlated with mPFS, although the association was not statistically significant \( (P = 0.128) \). PFS was 14.56 months in patients with low NLR values prior to chemotherapy initiation and 12.39 months in those with high NLR values.

In ovarian cancer, the prognostic significance of NLR has been shown in several studies [26, 42, 44, 53] including metaanalyses encompassing studies in either gynecological cancers or exclusively ovarian carcinomas [54]. In all the above referenced studies, increased NLR values were associated with worse prognosis and resistance to platinum-based therapy. It should be noted though that different cut-off limits were evaluated in these studies that enrolled mainly patients treated with primary debulking surgery.

Our study enrolled solely patients that underwent IDS after receiving three cycles of NACT. We report that NLR is associated with OS, but not PFS on univariate analysis. There is only a limited number of studies addressing this specific population. Kim et al. were the first to evaluate the predictive value of pretreatment NLR in ovarian cancer patients undergoing neoadjuvant chemotherapy in an Asian population [43]. In accordance with our findings, an elevated NLR defined as over 3.81 was independently associated with worse OS, but not PFS [43]. Of note, there was a significant association between PFS and the dynamic change in NLR during neoadjuvant chemotherapy (HR 2.07, 95% CI 1.32–3.25). A similar study used a cut-off value of 6 and again increased NLR was significantly associated with worse OS in univariate analysis (HR 1.06, 95% CI 1.01–1.13, \( P = 0.040 \)) but not in multivariate analysis (HR 1.05, 95% CI 0.99–1.12, \( P = 0.080 \)) [26]. There was also no significant association between NLR and PFS in this population (\( P = 0.084 \)). Finally, a sub analysis of MITO 24 study aimed to evaluate if an elevated NLR (defined as NLR > 3 alike our study) could associate with clinical outcome [42]. The study included both patients treated with PDS and patients undergoing NACT and IDS approach. Elevated NLR was independently associated with PFS (HR = 1.23, 95% CI 1.10–1.37), OS (HR = 1.41, 95% CI 1.23–1.62) and PFI at 6 months (OR = 2.52, 95% CI 1.30–4.87, \( P = 0.006 \)) and 12 months (OR = 2.05, 95% CI 1.05–4.01, \( P = 0.036 \)) [42]. Interestingly, NLR lost its predictive value within the bevacizumab-treated population. In our study we have included both patients that received bevacizumab and patients that did not. Bevacizumab administration was significantly associated with PFS and OS, but this association lost its significance in the multivariate analysis indicating that bevacizumab administration is not an independent determinant of survival in these patients. In addition, the groups of patients that received or not bevacizumab in our study were heterogenous and further evaluation of NLR predictive value within each one lacks clinical significance. Overall, our results are in agreement with those observed in other studies addressing women treated with NACT and IDS.

Apart from NLR, other systemic inflammatory response markers have gained attention during the past years. Platelet-to-lymphocyte ratio (PLR) has been proposed as an indicator of prognosis in epithelial ovarian cancer in numerous studies [55, 56]. Fibrinogen, as a key factor of coagulation cascade, also implicates solid tumors and cancer aggressiveness. Yang et al recently proposed the combination of preoperative fibrinogen and NLR (F-NLR) as a novel prognostic feature of ovarian cancer although not in patients treated with IDS [41]. The F-NLR showed greater sensitivity and specificity than did fibrinogen or NLR alone. C-reactive protein (CRP) has been validated as a predictive factor in solid tumors [57]. Moreover, lymphocyte to monocyte ratio has been related with ovarian cancer aggressiveness and clinical outcome in a number of studies [58, 59]. Collectively, NLR could be combined with other systemic markers to increase the accuracy achieved.

Apart though from its prognostic significance, NLR would be of value in ovarian cancer patients undergoing NACT, if it could predict response to chemotherapy as assessed currently by CRS. Bohm et al. initially demonstrated the prognostic significance of CRS score in terms of PFS and platinum sensitivity [11]. This initial observation was followed by others including our work validating the prognostic and/or predictive value of CRS in ovarian cancer patients undergoing NACT [15, 18, 20, 60, 61]. Recently, a metaanalysis of published studies have shown that optimal response to NACT - designated as CRS3 – is associated with both FPS and OS benefit and this could be determined by the molecular biology of the disease as CRS3 was more frequently encountered among BRCA1/2 mutant patients [23]. However, this is not supported by other studies [62, 63] while other parameters as is the extent of the disease at initial diagnosis should be taken into consideration when evaluating response to chemotherapy [22, 64, 65]. In our study, no specific association between CRS and NLR at diagnosis was noted. Analogous was the result in the previous study conducted in the Asian population [43]. The number of patients could be a limiting factor for both studies. However, it should be taken into consideration whether this negative finding could really reflect the lack of a biological association. In our previous analysis, increased lymphocytic infiltration was correlated to CRS denoting that the inflammatory milieu of the tumor could determine sensitivity to chemotherapy [19]. This observation was in accordance with the prognostic role of tumor-infiltrating lymphocytes in ovarian cancer [66] corresponding probably to NLR-low tumors. Therefore, larger studies are warranted to fully evaluate this association.

Finally, it should be noted that there is a great diversity regarding the cut-off values of NLR among studies [40]. This raises the question of the biological significance between NLR-high and low populations. Median cut-off for high NLR was 2.95 among studies evaluating OS and 2.79 among studies evaluating PFS in correlation with NLR [40]. NLR threshold applied ranged between 0.89 to 5.03 across different studies. On that basis, we used 3 as the cut-off value and defined NLR > 3 as high NLR value in our understudy population. However, it is evident that 72% of patients in our study were characterized as NLR-high by this binary classification. Obviously, these patients could not represent exclusively a population with adverse prognostic features. More likely, these patients designated as NLR-low in our study correspond to a population with minimal systemic inflammation and better prognostic features. This is most probably the reason that NLR lost its prognostic significance in the multivariate analysis.

Our study has some limitations. Firstly, the data was retrospectively collected and comprise a relatively small patient cohort from a single center. Moreover, there is a bias against ovarian cancer patients that could not eventually undergo IDS. Women with higher NLR values were more frequently unable to undergo debulking surgery than those with low NLR (21 vs 8 cases respectively). Although surgery was excluded from multivariate analysis, it may have still affected univariate analysis of NLR with PFS and OS. Finally, our study is based mainly on high grade ovarian cancer patients that could not be upfront debulked. Some studies support that the prognostic value of NLR may be greater in low or intermediate grade disease [40].

**Conclusions**
In conclusion, NLR could serve as a useful predictor of OS but not PFS in ovarian cancer patients receiving neoadjuvant treatment. High NLR defined as over 3 may indicate patients with worse prognosis. CRS score should be implemented in everyday clinical practice as a binary prognostication system to stratify ovarian patients at high risk for relapse. Both these biomarkers require further prospective validation, while their combination in nomograms along with other common prognostic factors could improve stratification of ovarian cancer patients undergoing NACT. This could be a useful tool to guide future clinical trial design and treatment personalization.

Declarations

ETHICS APPROVAL: Informed consent was obtained from all individual participants included in the study. The study has been performed in accordance with the 1964 Helsinki Declaration and has been approved by the Institutional Review Board of Alexandria University Hospital.

CONSENT FOR PUBLICATION

Written informed consent has been obtained from all the patients enrolled to publish this paper.

DATA AVAILABILITY STATEMENT

Data presented in our study can be found in the patients’ archives that are safely stored in our Institution. The datasets generated during the current study are available from the corresponding author upon request.

COMPETING INTERESTS

Dr Liontos has received honoraria by Roche, Astra Zeneca, Astellas, MSD, Janssen,BMS and IPSEN, Dr Koutsoukos has received honoraria by Roche, BMS, MSD and IPSEN, Dr. Zagouri receiving honoraria by Novartis, Eli-Lilly, Merck, Pfizer, and Roche Dr. Dimopoulos has received honoraria by Janssen, Celgene, Takeda, Aigen, Genesis Pharma and BMS Dr. Andrikopoulos, Dr Kaparelou, Dr Markellos, Dr Fiste, Dr Skafida, Dr Thomakos, Dr Haidopoulos and Dr Rodolakis declare no conflict of interest.

FUNDING

This research received no external funding.

AUTHORS’ CONTRIBUTIONS

Conceptualization: Michalis Liontos; Data curation: Michalis Liontos, Angeliki Andrikopoulou, Christos Markellos, Koutsoukos Konstantinos, Kaparelou Maria, Fiste Oraianthi, Skafida Efthymia, Haidopoulos Dimitris, Thomakos Nikolaos, Rodolakis Alexandros, Formal analysis: Angeliki Andrikopoulou, Christos Markellos, Kaparelou Maria, Fiste Oraianthi, Methodology: Michalis Liontos, Christos Markellos, Koutsoukos Konstantinos, Kaparelou Maria, Fiste Oraianthi, Skafida Efthymia, Project administration; Michalis Liontos, Haidopoulos Dimitris, Thomakos Nikolaos, Rodolakis Alexandros, Zagouri Flora, Dimopoulos Meletios-Athanasiou, Supervision: Liontos Michalis, Zagouri Flora, Dimopoulos Meletios-Athanasiou, Writing - original draft: Liontos Michalis, Angeliki Andrikopoulou, Writing - review & editing: Liontos Michalis, Angeliki Andrikopoulou

ACKNOWLEDGMENTS

Not Applicable

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424

2. Cancer Tomorrow. https://gco.iarc.fr/tomorrow/graphic-isotype?type=1&type_sex=0&mode=population&sex=2&populations=900&cancers=25&age_group=value&apc_male=0&apc_female=0&single_unit=50000&print=0. Accessed 4 May 2020

3. Prat J (2012) New insights into ovarian cancer pathology. Ann Oncol. https://doi.org/10.1093/annonc/mds300

4. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY (2016) Ovarian cancer. Nat Rev Dis Prim 2:1–22

5. Vergote I, Tropé CG, Amant F, et al (2010) Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. N Engl J Med 363:943–953

6. Onda T, Satoh T, Saito T, et al (2016) Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial. Japan Clinical Oncology Group Study JCOG0602. Eur J Cancer 64:22–31
7. Liu EL, Mi RR, Wang DH, Wang LQ, Zhang YM, Chen W (2017) Application of combined intraperitoneal and intravenous neoadjuvant chemotherapy in senile patients with advanced ovarian cancer and massive ascites. Eur J Gynaecol Oncol 38:209–213

8. Pölcher M, Mahner S, Ortmann O, et al (2009) Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer - A prospective multicenter phase II trial (PRIMOVAR). Oncol Rep 22:605–613

9. van der Burg MEL, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Pecorelli S (1995) The Effect of Debunking Surgery after Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer. N Engl J Med 332:629–634

10. Cooke SL, Brenton JD (2011) Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol 12:1169–1174

11. Böhm S, Faruqi A, Said I, et al (2015) Chemotherapy response score: Development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol 33:2457–2463

12. Böhm S, Le N, Lockley M, Brockbank E, Faruqi A, Said I, Jeyarajah A, Wuntakal R, Gilks B, Singh N (2019) Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: Updated Chemotherapy Response Score (CRS) results. Int J Gynecol Cancer 29:353–356

13. Glenn Mccluggage W, Judge MJ, Clarke BA, et al (2015) Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: Recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol 28:1101–1122

14. Said I, Böhm S, Beasley J, et al (2017) The chemotherapy response score (CRS): Interobserver reproducibility in a simple and prognostically relevant system for reporting the histologic response to neoadjuvant chemotherapy in Tuboovarian High-Grade Serous Carcinoma. Int J Gynecol Pathol 36:172–179

15. Ditzel HM, Strickland KC, Meserve EE, et al (2019) Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). Int J Gynecol Pathol 38:230–240

16. Santoro A, Angelico G, Pirematti A, et al (2019) Pathological chemotherapy response score in patients affected by high grade serous ovarian carcinoma: The prognostic role of omental and ovarian residual disease. Front Oncol. https://doi.org/10.3389/fonc.2019.00778

17. Williams AT, Ganesan R (2020) Role of the pathologist in assessing response to treatment of ovarian and endometrial cancers. Histopathology 76:93–101

18. Coghan E, Meniawy TM, Munro A, et al (2017) Prognostic role of histological tumor regression in patients receiving neoadjuvant chemotherapy for high-grade serous tubo-ovarian carcinoma. Int J Gynecol Cancer 27:708–713

19. Liointos M, Sotiropoulou M, Kaparelou M, et al (2020) Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy. Gynecol Oncol 157:599–605

20. Lee JY, Chung YS, Na K, Kim HM, Park CK, Nam EJ, Kim S, Kim SW, Kim YT, Kim HS (2017) External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Gynecol Oncol. https://doi.org/10.3802/jgo.2017.28.e73

21. Rajkumar S, Polson A, Nath R, Lane G, Sayasneh A, Jakes A, Begum S, Mehra G (2018) Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma. Gynecol Oncol 151:264–268

22. Petrillo M, Zannoni GF, Tortorella L, Pedone Anchora L, Salutari V, Ercoli A, Magaritti PA, Scambia G, Fagotti A (2014) Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. Am J Obstet Gynecol 211:632.e1-632.e8

23. Cohen PA, Powell A, Böhm S, et al (2019) Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecol Oncol 154:441–448

24. Templeton AJ, McNamara MG, Šeruga B, et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. J Natl Cancer Inst. https://doi.org/10.1093/jnci/dju124

25. Chen G, Zhu L, Yang Y, Long Y, Li X, Wang Y (2018) Prognostic role of neutrophil to lymphocyte ratio in ovarian cancer: A meta-analysis. Technol Cancer Res Treat. https://doi.org/10.1177/1533033818791500

26. Salman L, Sabah G, Jakobson-Setton A, Raban O, Yeoshoua E, Eitan R (2020) Neutrophil-to-lymphocyte ratio as a prognostic factor in advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy. Int J Gynecol Obstet 148:102–106

27. Jeerakompassawat D, Suprasert P (2020) Potential predictors for chemotherapeutic response and prognosis in epithelial ovarian, fallopian tube and primary peritoneal cancer patients treated with platinum-based chemotherapy. Obstet Gynecol Sci 63:55–63
28. Baert T, Van Camp J, Vanbrabrant L, Busschaert P, Laenen A, Han S, Van Nieuwenhuysen E, Vergote I, Coosemans A (2018) Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients. Gynecol Oncol 150:31–37

29. Badora-Rybicka A, Nowara E, Starzyczyzny-Slota D (2016) Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer. ESMO Open. https://doi.org/10.1136/esmoopen-2016-000039

30. Yıldız Y, Kucukzeybek Y, Alacacioglu A, et al (2017) Prognostic value of preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with epithelial ovarian cancer. Eur J Gynaecol Oncol 38:444–448

31. Komura N, Mabuchi S, Yokoi E, Kozasa K, Kuroda H, Sasano T, Matsumoto Y, Kimura T (2018) Comparison of clinical utility between neutrophil count and neutrophil–lymphocyte ratio in patients with ovarian cancer: a single institutional experience and a literature review. Int J Clin Oncol 23:104–113

32. Zhou M, Li L, Wang X, Wang C, Wang D (2018) Neutrophil-to-Lymphocyte Ratio and Platelet Count Predict Long-Term Outcome of Stage IIIC Epithelial Ovarian Cancer. Cell Physiol Biochem 46:178–186

33. Wu Y yang, Qin Y yuan, Qin J qiu, Zhang X, Lin F quan (2019) Diagnostic value of derived neutrophil-to-lymphocyte ratio in patients with ovarian cancer. J Clin Lab Anal. https://doi.org/10.1002/jcla.22833

34. Chen L, Wang X, Shu J, Xu S, Wu Q, Yu Y (2019) Diagnostic value of serum D-dimer, CA125, and neutrophil-to-lymphocyte ratio in differentiating ovarian cancer and endometriosis. Int J Gynecol Obstet 147:212–218

35. YILDIRIM M, DEMIR CENDEK B, FILIZ AVSAR A (2015) Differentiation between benign and malignant ovarian masses in the preoperative period using neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios. Mol Clin Oncol 3:317–321

36. Aotsuka A, Matsumoto Y, Arimoto T, et al (2019) Interleukin-17 is associated with expression of programmed cell death 1 ligand 1 in ovarian carcinoma. Cancer Sci 110:3068–3078

37. Santos ID, Jammal MR, Silveira TP, Murta EFC, Nomelini RS (2019) Stromal IL2 is related to the neutrophil/lymphocyte ratio in epithelial ovarian cancer. Pathologica 111:62–66

38. Marchetti C, Romito A, Musella A, Santo G, Palaia I, Perniola G, Di Donato V, Muzzii L, Benedetti Panici P (2018) Combined Plasma Fibrinogen and Neutrophil Lymphocyte Ratio in Ovarian Cancer Prognosis May Play a Role? Int J Gynecol Cancer 28:939–944

39. Ethier JL, Desautels DN, Templeton AJ, Oza A, Amir E, Lheureux S (2017) Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. Gynecol Oncol 145:584–594

40. Yang J, Ma J, Cheng S, Wang Y (2020) The combination of plasma fibrinogen concentration and neutrophil lymphocyte ratio (F-NLR) as a prognostic factor of epithelial ovarian cancer. Onco Targets Ther 13:7283–7293

41. Farolfi A, Scarpi E, Greco F, et al (2020) Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study. Sci Rep 10:1–8

42. Kim YJ, Lee I, Chung YS, Nam EJ, Kim S, Kim SW, Kim YT, Lee JY (2018) Pretreatment neutrophil-to-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer. Obstet Gynecol Sci 61:227–234

43. Williams KA, Labidi-Galy SI, Terry KL, Vitonis AF, Welch WR, Goodman A, Cramer DW (2014) Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecol Oncol 132:542–550

44. Grivennikov SI, Greten FR, Karin M (2010) Immunity, Inflammation, and Cancer. Cell 140:883–899

45. Babmias A, Gavalas NG, Karadimou A, Dimopoulos MA (2010) Immune response in ovarian cancer: How is the immune system involved in prognosis and therapy? Potential for treatment utilization. Clin Dev Immunol. https://doi.org/10.1155/2010/791603

46. Ocana A, Nieto-Jiménez C, Pardiella A, Templeton AJ (2017) Neutrophils in cancer: Prognostic role and therapeutic strategies. Mol Cancer. https://doi.org/10.1186/s12943-017-0707-7

47. Klink M, Jastrzembska K, Nowak M, Bednarska K, Szpakowski M, Szylo K, Sulowska Z (2008) Ovarian cancer cells modulate human blood neutrophils response to activation in vitro. Scand J Immunol 68:328–336

48. Lee WJ, Ko SY, Mohamed MS, Kenny HA, Lengyel E, Naora H (2019) Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. J Exp Med 216:176–194
50. Eo WK, Kim KH, Park EJ, Kim HY, Kim H bae, Koh SB, Namkung J (2018) Diagnostic accuracy of inflammatory markers for distinguishing malignant and benign ovarian masses. J Cancer 9:1165–1172

51. Yildirim MA, Seckin KD, Togrul C, Baser E, Karsli MF, Gungor T, Guleman HC (2014) Roles of neutrophil/lymphocyte and platelet/lymphocyte ratios in the early diagnosis of malignant ovarian masses. Asian Pacific J Cancer Prev 15:6881–6885

52. Bakacak M, Serin S, Ercan Ö, Köstü B, Bostanci MS, Bakacak Z, Kiran H, Kiran G (2016) Utility of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios to distinguish malignant from benign ovarian masses. J Turkish Ger Gynecol Assoc 17:21–25

53. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K (2009) Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 58:15–23

54. Yang Z, Gu JH, Guo CS, Li XH, Yang WC (2017) Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival of epithelial ovarian cancer: A systematic review and meta-analysis of observational studies. Oncotarget 8:46414–46424

55. Asher V, Lee J, Innamaa A, Bali A (2011) Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol 13:499–503

56. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T (2012) Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol 23:265–273

57. Shrotriya S, Walsh D, Nowacki AS, Lorton C, Aktas A, Hullihen B, Benanni-Baiti N, Hauser K, Ayvaz S, Estfan B (2018) Serum c-reactive protein is an important and powerful prognostic biomarker in most adult solid tumors. PLoS One. https://doi.org/10.1371/journal.pone.0202555

58. Eo WK, Chang HJ, Kwon SH, et al (2016) The lymphocyte-monocyte ratio predicts patient survival and aggressiveness of ovarian cancer. J Cancer 7:289–296

59. Cai L, Song Y, Zhao X (2020) Prognostic significance of lymphocyte monocyte ratio in patients with ovarian cancer. Med (United States). https://doi.org/10.1097/MD.0000000000019638

60. Michaan N, Chong WY, Han NY, Lim MC, Park SY (2018) Prognostic Value of Pathologic Chemotherapy Response Score in Patients with Ovarian Cancer after Neoadjuvant Chemotherapy. Int J Gynecol Cancer 28:1676–1682

61. Lawson BC, Euscher ED, Bassett RL, Liu J, Ramalingam P, Zhong Y, Fleming ND, Malpica A (2020) A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant? Am J Surg Pathol 44:206–213

62. Lee YJ, Kim HS, Rim JH, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT (2020) Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer. BMC Cancer. https://doi.org/10.1186/s12885-020-6688-8

63. Barrington DA, Felix AS, Owda R, et al (2020) Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations. Surg Oncol 34:40–45

64. Sassen S, Schmalfeldt B, Avril N, Kuhn W, Busch R, Höfler H, Fend F, Nährig J (2007) Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer. Hum Pathol 38:926–934

65. Liang M, Prendergast E, Staples J, Holschneider C, Cass I (2016) Complete Pathologic Response at Interval Debulking Surgery Following Neoadjuvant Chemotherapy Predicts Improved Survival in Women with Advanced Epithelial Ovarian Cancer in a Multi-institutional Cohort. Gynecol Oncol 143:197

66. Zhang L, Conejo-Garcia JR, Katsaros D, et al (2003) Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. N Engl J Med 348:203–213

Figures
Figure 1

Kaplan-Meier curves depicting progression-free survival (PFS) according to NLR status (blue line: NLR-low, red line: NLR-high)
Figure 2
Kaplan-Meier curves depicting progression-free survival (PFS) according to CRS (blue line: CRS1/2, red line: CRS3)
Figure 3

Association between OS and NLR status. (blue line: NLR-low, red line: NLR-high)

Figure 4

Survival Functions
Association of chemotherapy response score (CRS) with overall survival. (blue line: CRS1/2, red line: CRS3)